Loading...
StateHouse Holdings Inc.
STHZ.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.03
CA$0.00(0.00%)

Over the past four quarters, StateHouse Holdings Inc. demonstrated steady revenue growth, increasing from $25.34M in Q2 2023 to $27.77M in Q2 2024. Operating income reached $3.35M in Q2 2024, maintaining a consistent 12% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $5.20M, reflecting operational efficiency. Net income rose to $208708.00, with EPS at $0.001. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan